Bayer proposes to buy radiopharmaceutical partner Algeta for $2.4bn; offer increased, finalized
Bayer AG proposed to buy its radiopharmaceutical partner, publicly traded Algeta ASA, for NOK336 ($55.11) per share, a 27% premium, valuing Algeta at $2.4bn.
- Radiopharmaceuticals, Contrast Agents
- Full Acquisition
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com